Amgen profits top Wall Street expectations


Amgen, the world’s largest biotech company, reported higher-than-expected third quarter profit and revenue, helped by strong demand for its white blood cell booster, Neulasta, and increased sales of newer drugs, and the company raised it full-year forecast. The company recorded a $376 million charge related to restructuring moves announced July 29 and expects to take another charge of up to $150 million in the fourth quarter, as well as additional charges next year.

Read the source article at

About the Author

Leave a Reply